Table 2 Univariate analyses of outcome according to the ATG dose

From: Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation

  ATG < 6 mg/kg ATG ≥ 6 mg/kg p
  2 y% 95 CI 2 y% 95 CI
Acute GVHD
 Grade II–IV 13 8–18 21 7–32 0.334
 Grade III–IV 7 3–10 10 0–19 0.579
Chronic GVHD
All grades 40 32–47 40 22–54 0.824
Extensive 18 12–23 19 5–30 0.897
NRM 14 8–18 15 3–26 0.878
CIR 26 20–33 52 33–65 0.011
PFS 60 53–68 33 21–52 0.005
OS 64 57–62 49 35–68 0.041
GRFS 50 43–58 28 17–46 0.023
  1. GVHD graft-vs.-host disease, GRFS GVHD and relapse-free survival, NRM non-relapse mortality, CIR cumulative incidence of relapse, OS overall survival, PFS progression-free survival, 2-y% 2-year estimation, 95 CI 95% confidence interval